Articles tagged with Cancer Medication
Researchers at the University of Arizona have discovered ethylenedione, a diradical molecule that was previously thought to be elusive. The discovery has significant implications for understanding radical molecular species, industrial processes, and potentially even atmospheric chemistry and climate modeling.
Duke University researchers created a method to enhance tumor-frying nanoparticles with chemotherapeutic coatings, releasing drugs in heated tissue. The technique combines photothermal therapy with localized drug delivery, potentially increasing effectiveness.
New imaging technique using radioactive sodium fluoride allows doctors to visualize unstable calcium deposits in arteries, enabling early diagnosis and development of new medicines. The technique non-invasively detects calcification in atherosclerosis, potentially revolutionizing treatment for patients at risk.
A new Australian study has found a promising drug, PR-104, effective against aggressive T-ALL in laboratory models. The research team is now exploring the molecular biology behind AKR1C3, an enzyme that activates the drug.
Researchers developed a method to optically control microtubule inhibitor drugs with high spatial precision, allowing for targeted treatment of cancer cells. The technique uses blue light to switch on and off the drugs, eliminating systemic side effects and improving therapeutic efficacy.
Researchers at the University of Kentucky have identified a new mechanism for targeting multi-subunit complexes that are critical to viral, bacterial, or cancer function, reducing drug resistance. This approach could lead to more potent drugs with fewer side effects.
Researchers aim to understand how reading interventions impact math skills in children with combined reading and math disabilities. They will use fMRI methods to examine brain activity during reading and math tasks.
Researchers have developed a new cancer drug FY26 that is 49 times more potent than Cisplatin, effectively shutting down the metabolism of cancer cells. The drug works by forcing cancer cells to use their mitochondria, which are defective in healthy cells, leading to cell death.
Researchers at the University of Southern California's Keck Medicine have identified a potential treatment for primary effusion lymphoma, a rare and aggressive form of cancer affecting HIV/AIDS patients. The treatment involves combining FDA-approved immunomodulatory drugs with BRD4 inhibitors, showing promising results in animal models.
Researchers have found a potential treatment option for children with Ewing's sarcoma by combining two active ingredients, Olaparib and Trabectedin, which achieves complete remission in all cases. The combination enhances the sensitivity of cancer cells to these drugs, increasing its effect.
Scientists discover that Methotrexate, commonly used for arthritis, can also treat myeloproliferative neoplasms with fewer side effects and lower costs. This repurposed treatment could revolutionize the care of patients worldwide.
Researchers use electron cryo-microscopy to visualize proteasome complex in unprecedented detail, revealing target sites for potential cancer drugs. The study paves the way for more precise and effective treatments.
Researchers discovered that a melanoma mutation activates ketogenesis enzyme HMG-CoA lyase, turning on fat breakdown in cancer cells. This rewiring of metabolism may explain why V600E mutation is common in melanomas and provide alternative strategies to existing drugs targeting the mutation.
Researchers at Johns Hopkins have found that combining fostamatinib with paclitaxel can reduce tumor size in ovarian cancer cells by up to 87 percent. The combination therapy may provide a new treatment option for patients with recurrent advanced ovarian cancer who have developed resistance to standard treatments.
Researchers found improved median survival of patients with low-grade gliomas increasing from 44 months to 57 months between 1999 and 2010. The study suggests more effective chemotherapies contribute to the increased survival, despite a decrease in radiation therapy use.
Researchers at Ohio State University developed nanoparticles coated with chitosan that effectively target and kill cancer stem-like cells. The study found that these nanoparticles can increase the cytotoxicity of doxorubicin without systemic toxic side effects.
Researchers found that PI3K inhibitors reprogram the mitochondria of tumor cells, causing them to produce energy in a localized manner, leading to a more aggressive and invasive phenotype. This paradoxical response may offer a new therapeutic angle for treating cancers.
Researchers at SLU developed a drug that targets cancer metabolism, stopping most kinds of cancer by cutting off the energy supply. The drug, SR9243, has shown promising results in cultured cancer cells and human tumor cells grown in animal models.
Scientists at Salk Institute and Sanford Burnham Prebys Medical Discovery Institute have developed a drug that inhibits the first step of autophagy, a process used by cancer cells to recycle nutrients. This breakthrough opens new avenues for treating resistant cancers.
A UCL-led study has found that a small molecule drug, trametinib, can delay the ageing process in animals, including fruit flies. The treated fruit flies lived 12% longer than average, staying healthier for longer.
A study from VA and the University of Alabama at Birmingham found that honokiol shuts down cancer cells in lab, blocking EGFR protein in squamous cell head and neck cancers. The compound has shown promise as a treatment option for this aggressive form of cancer.
Researchers at the University of Toronto have developed a new device that can track chemical signals within cells, allowing for faster and more accurate detection of cancerous growth. The device uses digital microfluidics to deliver rapid sequences of chemicals, enabling scientists to study cell responses in unprecedented detail.
A multimillion-dollar research partnership at the University of Alberta is developing small molecules that can reactivate a patient's immune system to fight cancer. The team plans to have a 'lead structure' drug ready by the end of the second year, with the potential for human trials by 2020.
Researchers found a higher risk of malignant melanoma among Viagra users, but evidence points to socioeconomic and lifestyle factors as the cause. The study analyzed over 20,000 medical records and found no increased risk among those with more prescriptions or advanced stages of the disease.
Current blood cancer drug prices are too high to be considered cost-effective in the US, according to a recent MD Anderson Cancer Center study. The researchers found that 63% of 20 studies evaluated had costs per additional life-year higher than $50,000, indicating that current prices cannot be justified based on improved quality of life.
Dr. Maurizio D'Incalci receives the first Pezcoller-Prodi Award in recognition of his work on translational cancer research and therapeutic oncology. The award highlights his contributions to the development of novel anticancer drugs, including trabectedin.
A recent study found that adult Americans aged 25 and older have become increasingly obese, with 67.6 million estimated to be obese and 65.2 million considered overweight.
Researchers at Mayo Clinic have identified a new epigenomic block that could help stop the progression of many late-stage cancers. This discovery has the potential to improve diagnosis and treatment of advanced disease across various cancer types.
Researchers are using pet dogs with naturally occurring tumors to test new cancer drugs, which could lead to innovative therapies for both humans and animals. The dogs' physiological similarities to humans and conserved genetics between some dog and human cancers make them an ideal model for studying new treatments.
A new study finds that providing direct assistance, such as counseling and nicotine replacement therapy, significantly improves the likelihood of patients quitting smoking. The research team analyzed data from over 1,600 participants who underwent lung cancer screening, finding that active clinician support increased quit rates by 40%.
The Pew Charitable Trusts and Alexander and Margaret Stewart Trust announced five early-career cancer researchers as Pew-Stewart Scholars. They will receive flexible funding to pursue innovative work aimed at advancing progress toward a cure for cancer.
Researchers at Washington University School of Medicine identified a key player in maintaining brain tumor stem cells' ability to survive and replenish themselves. Disrupting this process using protein CDC20 has been shown to reduce tumor growth by up to 95 percent in mice, offering new hope for treating glioblastoma.
Researchers found that mutations in ARID1a gene sensitize certain tumors to PARP inhibitor drugs, allowing for more effective treatment options. The study highlights the importance of using genomic information to guide cancer therapy and identify precise treatments for individual patients.
Researchers have developed a new drug that stimulates tissue stem cells to repair damaged tissues more quickly, showing promise in treating diseases such as ulcerative colitis and bone marrow transplants. The drug, known as SW033291, increases prostaglandin E2 levels and promotes tissue healing without adverse side effects.
A new study published in the American Journal of Public Health found that messages with images depicting the harsh realities of melanoma are more powerful than text-only warnings in persuading young women to reconsider indoor tanning. Loss-framed messages emphasizing the risks of indoor tanning were more effective in decreasing intenti...
Researchers have designed nanoparticles that specifically target cancer stem cells, which are tough to kill with conventional drugs. The treatment successfully killed CSCs and destroyed tumors in mice tests, with no obvious side effects. This therapy may help overcome the defenses of these hardy cells.
Researchers at Johns Hopkins Medicine discovered a protein-signaling process that accelerates the work of the most frequently mutated gene in adult leukemia. A combination of two drugs targeting this process and the gene itself slowed leukemia cell growth in mice, suggesting potential for improved treatment outcomes.
A phase III clinical trial shows necitumumab significantly improves median overall survival in stage IV squamous non-small cell lung cancer patients. The drug's 'fully human' EGFR antibody approach demonstrates potential as a novel immunotherapy strategy.
A small clinical trial found that men with advanced prostate cancer and the AR-V7 gene variant respond to chemotherapy just as well as those without the variant. The study's findings may lead to improved treatment decision-making for patients with prostate cancer.
Researchers at NYU Langone Health have successfully halted and reversed the growth of certain cancerous white blood cells in T-cell acute lymphoblastic leukemia (T-ALL) by blocking a specific protein receptor called CXCR4.
Researchers use 'Google Maps' for cancer genome analysis, identifying potential drug targets and monitoring treatment response. They provide a comprehensive view of the patient's multiple myeloma genome, showing notable mutations and larger-scale changes over time.
A new theranostic agent, I-124 PEG-AVP0458, has shown promise in targeting both ovarian and prostate cancer cells for imaging and treatment. The drug compound attaches itself to the targeted tumor sites via positron emission tomography (PET) scanners, enabling personalized cancer therapy.
Researchers at the Weizmann Institute have developed a three-pronged approach to prevent lung cancer cells from developing resistance to chemotherapy. The new strategy involves targeting two main growth receptor siblings, HER2 and HER3, in addition to an existing anti-EGFR antibody.
Intravenous nutrition source Intralipid reduces chemotherapy side effects by increasing drug bioavailability and targeting cancer treatment, allowing more drugs to reach tumor sites and reducing toxicity.
Researchers from Mount Sinai Health System will present updates on a lymphoma vaccine clinical trial and new treatment strategies in relapsed multiple myeloma. Preliminary results show patients achieving partial or complete clinical remissions, including those with advanced stage disease.
Researchers at VCU Massey Cancer Center have found a promising combination of an experimental drug and common antibiotic Minocycline to target pancreatic cancer cells. The synergistic effect of the two drugs eliminated Stat3 expression, a key protein regulating tumor growth.
The study found that nivolumab improved median overall survival by 2.4 months and doubled the one-year survival rate compared to chemotherapy. The immunotherapy drug also reduced the risk of dying from lung cancer by 41%.
Researchers have discovered how combining AKT inhibitors with radiotherapy may improve cancer treatment outcomes. The study found that targeting specific genes can enhance the efficacy of radiotherapy across various cancer types.
The ESMO Magnitude of Clinical Benefit Scale (ESMO-MCBS) provides a rational approach to grading the magnitude of clinical benefit of anti-cancer medicines. The scale will be applied to new drugs approved by the EMA, with high-scoring drugs highlighted in the ESMO Clinical Practice Guidelines.
Pacritinib significantly reduced severe spleen enlargement and debilitating side effects in over 20% and 46% of patients, respectively. The therapy also showed promise in treating thrombocytopenia, a life-threatening condition often associated with myelofibrosis.
A recent Mayo Clinic study found that combining the targeted drug ibrutinib with standard chemotherapy significantly reduces the risk of death or cancer progression in patients with relapsed CLL or SLL. The treatment results in a nearly 80% reduction in mortality, offering new hope for longer disease control and decreased risk of relapse.
A Yale University study found that removing more tissue during a partial mastectomy can spare thousands of breast cancer patients from a second surgery. The study showed that cavity shave margins reduced positive margin rates in half without compromising cosmetic outcomes or increasing complication rates.
A University of Colorado Cancer Center study found significant genetic differences between colorectal cancer tumors in young and old patients. The study identified altered gene signaling pathways, including PPAR and IGF1R, which may be involved in the development of younger CRC tumors.
Women treated for gynecologic cancers experience decreased sexual activity, with younger and premenopausal women at higher risk. Counseling during treatment may help alleviate long-term effects on sexual health.
Jim Allison's pioneering work on T-cell response mechanisms led to the development of ipilimumab, a melanoma treatment that has shown unprecedented results in survival rates. His research continues to open new avenues for cancer treatment through immune checkpoint blockade.
The myChoice HRD test predicts response to DNA-damaging agents in ovarian, breast, and pancreatic cancers. A score of ?42 indicates a loss of DNA repair function and reflects tumor sensitivity to PARP inhibitors and platinum-based therapies.
Researchers identified a genetic biomarker that can predict which cancer patients will respond to immunotherapy drugs like pembrolizumab. Patients with mismatch repair gene defects showed improved responses to the treatment, offering hope for previously failed patients. Larger studies are needed to assess the potential for clinical use.
University Hospitals Case Medical Center researchers will present data from several new studies evaluating a potential novel combination treatment for cancer patients with advanced solid tumors. Additionally, experts will analyze gene mutations in small cell lung cancer, revealing significant clinical correlation to overall survival an...
Researchers at Penn's Abramson Cancer Center have made significant advancements in treating advanced BRCA-related ovarian cancer, with over a third of patients responding to olaparib. Additionally, targeted therapy everolimus shows promise in stabilizing disease for advanced thyroid cancer patients who stop responding to sorafenib, and...
A phase I/II clinical trial found that brigatinib responded to treatment in 58 of 78 ALK+ patients, with a 13.4-month progression-free survival rate for those previously treated with crizotinib. Brigatinib also showed promise in treating brain metastases, with a 30% decrease in tumor size and controlled disease for 15.6 months.